Abstract
Background
Methods
Results
Conclusions
Key Indexing Terms
Introduction
- Ersbøll M
- Valeur N
- Mogensen UM
- Andersen MJ
- Møller JE
- Velazquez EJ
- et al.
- Biering-Sørensen T
- Biering-Sørensen SR
- Olsen FJ
- Sengeløv M
- Jørgensen PG
- Mogelvang R
- et al.
Methods
Study population
Study design
Definitions
Two-dimensional transthoracic echocardiography
- Lang RM
- Bierig M
- Devereux RB
- Flachskampf FA
- Foster E
- Pellikka PA
- et al.
Two-dimensional speckle-tracking echocardiography
Intra-observer and inter-observer reproducibility
Psychological evaluation in the study population
Inventories
- 1.Screening Questionnaire: Designed by the investigators, this form consists of questions including socio-demographical characteristics such as age, sex, education level, marital status, lifestyle features, and questions about COVID-19 experience and opinions.
- 2.DASS-21: This self-report inventory evaluates psychological symptoms in the past week. DASS-21 consists of 21 questions on a 0–3 point scale. Depression, anxiety, and stress were measured as separate subgroups, with a total of seven questions each. Higher scores indicate a higher level of psychological distress. The scores are grouped in five levels ranging from normal to mild, moderate, severe, and extremely severe, according to different cut-off values.25This widely used tool has been translated into Turkish and validated for the Turkish population.26
- 3.IES-R: This is also a widely used self-report scale for screening distressful psychological symptoms associated with a traumatic life event. In our investigation, we changed the word “event” to “COVID-19 disease” in order to make it easier for the participants to understand the questions. IES-R consists of 22 items scored from 0 to 4 and three subscales, i.e.intrusion, avoidance, and hyperarousal. IES-R is not a diagnostic tool for post-traumatic stress disorder; however, higher scores indicate higher negative psychological reactions to the event.27The Turkish validity and reliability of this score was made by Çorapçıoğlu et al. in 2006.28
Statistical analysis
Results
Clinical and sociodemographic characteristics and COVID-19 related questions
Total patients (n=108) | Control (n=37) | Home recovery (n=48) | Hospital recovery (n=23) | p- value | |
---|---|---|---|---|---|
Clinical characteristics | |||||
Age, (years) | 40.4 ± 10 | 38.2 ± 7.7 | 42.4 ± 11.8 | 40.6 ± 9 | 0.181 |
Sex Male n, (%) Female n, (%) | 45 (41.7 %) 63 (58.3 %) | 11 (29.7 %) 26 (70.3 %) | 23 (47.9 %) 25 (52.1 %) | 11 (47.8 %) 12 (52.2 %) | 0.192 |
HT, n (%) | 24 (22.2 %) | 5 (13.5 %) | 10 (20.8 %) | 9 (39.1 %) | 0.065 |
DM, n (%) | 13 (12 %) | 4 (10.8 %) | 3 (6.3 %) | 6 (26.1 %) | 0.053 |
BMI (kg/m2) | 28.5 ± 4.5 | 28.7 ± 3.9 | 27.9 ± 4.9 | 29.2 ± 4.1 | 0.052 |
Psychiatric disorder, n(%) | 14 (13 %) | 4 (10.8 %) | 6 (12.5 %) | 4 (17.4 %) | 0.755 |
Smoking, n (%) | 25 (23.1 %) | 13 (35.1 %) | 9 (18.8 %) | 3 (13 %) | 0.089 |
Pneumonia on CT | 63 (58.3 %) | - | 40 (83.3 %)c | 23 (100 %)c | 0.004 |
Follow-up durations, (days) | 118 (30-197) | - | 110 (37-191)c | 155 (31-197)c | 0.005 |
Hospital stay, (days) | 32 (2-44) | - | 0c | 32 (2-44)c | <0.001** |
Laboratory findings on the day of follow-up visits | |||||
Fasting Plasma Glucose (mg/dl) | 100 ± 28.1 | 94.9 ± 27.2b | 97.6 ± 22.1c | 111.9 ± 36.6b,c | 0.027 |
BUN (mg/dl) | 13.3 ± 5.4 | 11.8 ± 4.5b | 13.3 ± 5.5 | 15.2 ± 5.9b | 0.036 |
Creatinine (mg/dl) | 0.7 ± 0.2 | 0.7 ± 0.2 | 0.8 ± 0.2 | 0.9 ± 0.3 | 0.137 |
AST (U/I) | 18.1 (10-83) | 17.7 (11-83) | 18.1 (12-69) | 18.5 (10-68) | 0.798 |
ALT (U/I) | 17.7 (5-97) | 16.1 (7-62) | 16.1 (6-87) | 21.5 (5-97) | 0.462 |
LDH (U/I) | 189.9 ± 41.1 | 170.1 ± 33.7a,b | 190 ± 29.1a | 216.7 ± 55.0b | 0.001 |
Hgb (gr/dl) | 13.3 ± 1.7 | 13.6 ± 1.3 | 13.1 ± 1.6 | 13.1 ± 2.2 | 0.331 |
WBC (10³/µl) | 6.6 (2.4-19.6) | 6.8 (3.9-12.4) | 6 (3.4-10.8) | 7 (2.4-19.6) | 0.177 |
Lymphocytes (10³/µl) | 2.2 (0.5-6.3) | 2.2 (1.1-6.3) | 2.2 (1-3.8) | 2.1 (0.5-4.1) | 0.397 |
CRP (mg/L) | 1.8 (0-39) | 1.4 (0-28)b | 1.5 (0-17)c | 6.1 (1-39)b,c | 0.003 |
D-dimer (µg/L) | 320 (169-4810) | 280 (169-560) | 275 (190-1230) | 390 (180-4810) | 0.051 |
Ferritin (ng/ml) | 54 (4-1010) | 42.5 (6-246)b | 40.7 (4-358)c | 83.9 (11-1010)b,c | 0.027 |
Hs-troponin-T (pg/ml) | 3.8 (3-59) | 3 (3-5)b | 3.5 (3-59)c | 7.7 (3-41)b,c | <0.001 |
Pro-BNP (pg/ml) | 63.3 (5-1674) | 33.1 (5-97) | 66.3 (5-1674) | 72.9 (5-1258) | 0.114 |
Treatment | |||||
Hydroxychloroquine, (%) | 48 (44.4 %) | - | 26 (54.2 %)c | 22 (95.7 %)c | <0.001 |
Azithromycin, n (%) | 20 (18.7 %) | - | 3 (6.3 %)c | 17 (77.3 %)c | <0.001 |
Favipiravir, n (%) | 30 (28 %) | - | 16 (33.3 %)c | 14 (63.6 %)c | 0.040 |
Heparin, n (%) | 27 (25 %) | - | 6 (12.5 %)c | 21 (91.3 %)c | <0.001 |
Steroid, n (%) | 6 (5.6 %) | - | 1 (2.1 %)c | 5 (21.7 %)c | 0.019 |
Immune modulator, n (%) | 14 (13 %) | - | 1 (2.1 %)c | 13 (56.3 %)c | <0.001 |
Antibiotics, n (%) | 25 (23.1 %) | - | 9 (18.8 %)c | 16 (69.6 %)c | <0.001 |
ICU admission, n (%) | 4 (3.7 %) | - | 0 (0%)c | 4 (17.4 %)c | 0.009 |
NIMV/HFNC, n (%) | 8 (7.4 %) | - | 0 (0 %)c | 8 (34.8 %)c | <0.001 |
Orotracheal intubation | 4 (3.7%) | - | 0 (0%)c | 4 (17.4 %)c | 0.009 |
Echocardiographic Findings | |||||
LVEDV (ml) | 136.6 ± 23.3 | 131.9 ± 19.7 | 137.6 ± 23.7 | 142.1 ± 26.9 | 0.264 |
LVESV (ml) | 54.6 ± 13.1 | 51.4 ± 11.3 | 56.9 ± 14.5 | 55.1 ± 12.2 | 0.203 |
LVEDD (mm) | 45.2 ± 3.7 | 44.5 ± 3.2 | 45.3 ± 3.8 | 46 ± 4.3 | 0.264 |
LVEF (%) | 64.8 ± 4.9 | 65.8 ± 4.9 | 63.9 ± 5.1 | 64.8 ± 4 | 0.364 |
LAVI (ml/m²) | 20.9 ± 7 | 21.1 ± 5.8 | 21.4 ± 8.5 | 19.4 ± 5.6 | 0.690 |
LA (mm) | 35.2 ± 4.5 | 33.8 ± 3.5b | 35.3 ± 4.7 | 37.2 ± 4.6b | 0.045 |
E/A ratio | 1.1 ± 0.3 | 1.3 ± 0.3a,b | 1 ± 0.3a,c | 0.8 ± 0.3b,c | <0.001 |
E/e’ ratio | 8.2 ± 2.9 | 7.4 ± 1.9 | 8.3 ± 3.3 | 9.2 ± 3.2 | 0.061 |
TAPSE (mm) | 21 ± 3.4 | 21.1 ± 3.2 | 20.9 ± 3.7 | 20.9 ± 3.3 | 0.940 |
SPAP (mmHg) | 25.7 ± 5.2 | 24.9 ± 4.5 | 25.8 ± 5.8 | 26.4 ± 4.9 | 0.645 |
LVGLS (%) | -16.2 ± 3.4 | -17.8 ± 2.7a,b | -15.5 ± 3.7a | -15,1 ± 2.8b | 0.002 |

IES-R and DASS-21 scores of participants

Echocardiographic characteristics

LVGLS | Variable | r | p |
---|---|---|---|
Total DASS-21 Score | −0.251 | 0.020* | |
DASS-21 Depression Score | −0.168 | 0.119 | |
DASS-21 Anxiety Score | −0.285 | 0.008* | |
DASS-21 Stress Score | −0.178 | 0.098 | |
IES-R Total Score | −0.291 | 0.007* | |
IES-R Intrusion Score | −0.367 | 0.001* | |
IES-R Avoidance Score | −0.196 | 0.069 | |
IES-R Hyperarousal Score | −0.188 | 0.081 |

Total patients | Patients with comorbidity | Patients with severe pneumonia | |||||
---|---|---|---|---|---|---|---|
LVGLS | Variable | r | p | r | p | r | p |
Total DASS-21 Score | −0.251 | 0.020* | −0.232 | 0.139 | −0.366 | 0.135 | |
DASS-21 Depression Score | −0.168 | 0.119 | −0.232 | 0.140 | −0.461 | 0.054 | |
DASS-21 Anxiety Score | −0.285 | 0.008* | −0.195 | 0.215 | −0.203 | 0.419 | |
DASS-21 Stress Score | −0.178 | 0.098 | −0.211 | 0.174 | −0.485 | 0.041* | |
IES-R Total Score | −0.291 | 0.007* | −0.495 | 0.001* | −0.716 | 0.002* | |
IES-R Intrusion Score | −0.367 | 0.001* | −0.470 | 0.002* | −0.666 | 0.004* | |
IES-R Avoidance Score | −0.196 | 0.069 | −0.341 | 0.027* | −0.462 | 0.054 | |
IES-R Hyperarousal Score | −0.188 | 0.081 | −0.419 | 0.006* | −0.500 | 0.041* |


LVEDV | LVESV | LVEF | LAVI | LV Mass Index | E/A | E/e’ | ||
---|---|---|---|---|---|---|---|---|
Total DASS-21 Score | r | −0.027 | −0.004 | −0.019 | −0.095 | 0.102 | −0.103 | 0.056 |
p | 0.787 | 0.967 | 0.850 | 0.378 | 0.330 | 0.302 | 0.571 | |
DASS-21 Depression Score | r | −0.128 | −0.036 | −0.069 | −0.064 | −0.002 | −0.003 | −0.041 |
p | 0.194 | 0.719 | 0.487 | 0.550 | 0.986 | 0.976 | 0.680 | |
DASS-21 Anxiety Score | r | −0.027 | −0.034 | −0.003 | −0.264 | 0.013 | −0.133 | 0.137 |
p | 0.787 | 0.730 | 0.978 | 0.013* | 0.904 | 0.180 | 0.168 | |
DASS-21 Stress Score | r | −0.044 | −0.012 | 0.021 | −0.017 | 0.105 | −0.123 | 0.053 |
p | 0.656 | 0.901 | 0.828 | 0.876 | 0.312 | 0.211 | 0.593 | |
IES-R Total Score | r | 0.047 | 0.047 | −0.025 | −0.135 | 0.079 | −0.149 | 0.033 |
p | 0.637 | 0.636 | 0.798 | 0.216 | 0.459 | 0.136 | 0.745 | |
IES-R Intrusion Score | r | 0.046 | 0.051 | −0.029 | −0.059 | 0.029 | −0.156 | 0.043 |
p | 0.646 | 0.607 | 0.767 | 0.586 | 0.786 | 0.116 | 0.671 | |
IES-R Avoidance Score | r | 0.045 | 0.017 | 0.023 | −0.125 | 0.085 | −0.111 | 0.067 |
p | 0.647 | 0.866 | 0.819 | 0.246 | 0.419 | 0.264 | 0.504 | |
IES-R Hyperarousal Score | r | −0.045 | 0.027 | −0.114 | −0.263 | 0.092 | −0.055 | 0.071 |
p | 0.649 | 0.781 | 0.248 | 0.027* | 0.380 | 0.580 | 0.474 |
LVGLS | Variable | r | p |
---|---|---|---|
Age | −0.329 | 0.005* | |
Sex | −0.213 | 0.044* | |
BMI | −0.461 | <0.001* | |
Educational Level | 0.381 | <0.001* | |
Marital Status | −0.273 | 0.010* | |
Home Arrangement | −0.027 | 0.803 | |
Anxiety about re-infection | −0.169 | 0.186 | |
Informed about COVID | 0.131 | 0.219 |
Variable | β | 95 % Confidence Interval | p-value |
---|---|---|---|
Age | 0.002 | −0.100 to 0.104 | 0.964 |
Sex | −1.261 | −2.778 to 0.256 | 0.102 |
Educational Level | 1.432 | 0.350 to 2.514 | 0.010* |
Marital Status | −0.897 | −2.573 to 0.779 | 0.289 |
DASS-21 Anxiety Score | 0.146 | −0.059 to 0.351 | 0.160 |
Total DASS-21 Score | −0.186 | −0.354 to -0.018 | 0.030* |
Total Patients (n=108) | Control (n=37) | Home Recovery (n=48) | Hospital Recovery (n=23) | p-value | |
---|---|---|---|---|---|
Age (years) | 40.4 ± 10 | 38.2 ± 7.7 | 42.4 ± 11.8 | 40.6 ± 9 | 0.181 |
Sex Male (n, %) Female (n, %) | 45 (41.7 %) 63 (58.3 %) | 11 (29.7 %) 26 (70.3 %) | 23 (47.9 %) 25 (52.1 %) | 11 (47.8 %) 12 (52.2 %) | 0.192 |
Educational Level | |||||
Primary School (n, %) | 38 (35.2 %) | 3 (8.1 %)a,b | 25 (52.1 %)a | 10 (43.5 %)b | <0.001 |
High School (n, %) | 25 (23.1 %) | 6 (16.2 %) | 11 (22.9 %) | 8 (34.8 %) | 0.253 |
University (n, %) | 45 (41.7 %) | 28 (75.7 %)a,b | 12 (25 %)a | 5 (21.7 %)b | <0.001 |
Marital Status | |||||
Single (n, %) | 24 (22.4 %) | 13 (35.1 %)b | 9 (19.1 %) | 2 (8.7 %)b | 0.042 |
Married (n, %) | 76 (71 %) | 22 (59.5 %) | 36 (76.6 %) | 18 (78.3 %) | 0.193 |
Divorced or Widowed (n, %) | 7 (6.5 %) | 2 (5.4 %) | 2 (4.3 %) | 3 (13 %) | 0.345 |
Home Arrangement | |||||
Sole Occupant (n, %) | 7 (6.5 %) | 5 (13.5 %) | 2 (4.3 %) | 0 (0 %) | 0.081 |
With Partner/ Housemate (n,%) | 94 (87.9 %) | 29 (78.4 %) | 42 (89.4 %) | 23 (100 %) | 0.053 |
With Family/ Children (n, %) | 6 (5.6 %) | 3 (8.1 %) | 3 (6.4 %) | 0 (0 %) | 0.395 |
Smoking (n, %) | 25 (23.1 %) | 13 (35.1 %) | 9 (18.8 %) | 3 (13 %) | 0.089 |
Alcohol Use (n, %) | 11 (10.3 %) | 7 (19.4 %)b | 4 (8.3 %) | 0 (0 %)b | 0.047 |
Comorbidity (n, %) | 47 (43.5 %) | 10 (27 %)b | 20 (41.7 %)c | 17 (73.9 %)b,c | 0.002 |
Psychiatric disorder, (n, %) | 14 (13 %) | 4 (10.8 %) | 6 (12.5 %) | 4 (17.4 %) | 0.755 |
Informed about COVID-19 | 65 (60.2 %) | 30 (81.1 %)a,b | 25 (52.1 %)a | 10 (43.5 %)b | 0.005 |
Anxiety about re-infection | 52 (72.2 %) | - | 39 (83 %) | 18 (78.3 %) | 0.634 |
Total Patients (n=108) | Control (n=37) | Home Recovery (n=48) | Hospital Recovery (n=23) | p-value | |
---|---|---|---|---|---|
Total DASS-21 Score | 7 (0-44) | 5 (0-13)a,b | 8 (1-44)a | 8 (3-38)b | 0.005 |
DASS-21, Depression Score | 1 (0-15) | 1.5 (0-7) | 1 (0-15) | 2 (0-13) | 0.623 |
DASS-21 Depression | |||||
Normal (n, %) | 87 (80.6 %) | 31 (83.8 %) | 38 (79.2 %) | 18 (78.3 %) | 0.826 |
Mild (n, %) | 6 (5.6 %) | 4 (10.8 %) | 1 (2.1 %) | 1 (4.3 %) | 0.211 |
Moderate (n, %) | 9 (8.3 %) | 1 (2.7 %) | 6 (12.5 %) | 2 (8.7 %) | 0.268 |
Severe (n, %) | 2 (1.9 %) | 0 (0 %)b | 0 (0 %)c | 2 (8.7 %)b,c | 0.023 |
Extremely Severe (n, %) | 4 (3.7 %) | 1 (2.7 %) | 3 (6.3 %) | 0 (0 %) | 0.394 |
DASS-21 Anxiety Score | 5 (0-38) | 1 (0-13)a,b | 6 (0-25)a | 8 (0-38)b | <0.001 |
DASS-21 Anxiety | |||||
Normal (n, %) | 71 (65.7 %) | 32 (86.5 %)a,b | 28 (58.3 %)a | 11 (47.8 %)b | 0.003 |
Mild (n, %) | 21 (19.4 %) | 3 (8.1 %)b | 8 (16.7 %)c | 10 (43.5 %)b,c | 0.003 |
Moderate (n, %) | 7 (6.5 %) | 1 (2.7 %) | 6 (12.5 %) | 0 (0 %) | 0.069 |
Severe (n, %) | 4 (3.7 %) | 0 (0 %) | 3 (6.3 %) | 1 (4.3 %) | 0.313 |
Extremely Severe (n, %) | 5 (4.6 %) | 1 (2.7 %) | 3 (6.3 %) | 1 (4.3 %) | 0.741 |
DASS-21 Stress Score | 3 (0-15) | 2.5 (0-6) | 3 (0-15) | 3 (1-13) | 0.133 |
DASS-21 Stress | |||||
Normal (n, %) | 98 (90.7 %) | 36 (97.3 %) | 40 (83.3 %) | 22 (95.7 %) | 0.058 |
Mild (n, %) | 4 (3.7 %) | 0 (0 %) | 4 (8.3 %) | 0 (0 %) | 0.075 |
Moderate (n, %) | 2 (1.9 %) | 0 (0 %) | 2 (4.2 %) | 0 (0 %) | 0.280 |
Severe (n, %) | 2 (1.9 %) | 0 (0 %) | 1 (2.1 %) | 1 (4.3 %) | 0.472 |
Extremely Severe (n, %) | 2 (1.9 %) | 1 (2.7 %) | 1 (2.1 %) | 0 (0 %) | 0.742 |
Impact of Events Total Score (IES-R) | 14 (1-66) | 13 (1-32)b | 13 (4-66)c | 20 (5-58)b,c | 0.024 |
IES-R Intrusion Score | 4 (0-25) | 3 (0-10)a,b | 5 (0-25)a | 7 (0-20)b | 0.010 |
IES-R Avoidance Score | 7 (0-27) | 7 (0-16) | 5 (1-27) | 10 (2-22) | 0.078 |
IES-R Hyperarousal Score | 2 (0-17) | 2 (0-10)a,b | 3 (0-17)a | 3 (0-16)b | 0.024 |
Discussion
Strengths of the study
Limitations of the study
Conclusions
Author contributions
Funding
Declaration of Competing Interest
Acknowledgments
References
- A novel coronavirus from patients with pneumonia in China, 2019.N Engl J Med. 2020; 382: 727-733
- Prevalence of post-traumatic stress disorder among survivors of severe COVID-19 infections: a systematic review and meta-analysis.J Affect Disord. 2022; 299: 52-59
- COVID-19 pandemic and mental health consequences: systematic review of the current evidence.Brain Behav Immun. 2020; 89: 531-542
- Research on the psychological status and influencing factors of novel coronavirus pneumonia patients and people under medical observation.J Nurs Adm. 2020; 20: 247-251
- Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors.Brain Behav Immun. 2020; 89: 594-600
- The psychological impact of quarantine and how to reduce it: rapid review of the evidence.Lancet. 2020; 395: 912-920
- Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.Lancet Psychiatry. 2020; 7: 611-627
- Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China.Psychol Med. 2021; 51: 1052-1053
- Depression and anxiety in heart failure: a review.Harv Rev Psychiatry. 2018; 26: 175-184
- Posttraumatic stress disorder and cardiovascular disease.Prog Cardiovasc Dis. 2013; 55: 548-556
- Post-traumatic stress disorder, coronary atherosclerosis, and mortality.Am J Cardiol. 2011; 108: 29-33
- Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: data linkage study of 1.9 million women and men.PLoS One. 2016; 11e0153838
- Posttraumatic stress disorder and incident heart failure among a community-based sample of US veterans.Am J Public Health. 2015; 105: 757-763
- Evaluation of biventricular function in patients with COVID-19 using speckle tracking echocardiography.Int J Cardiovasc Imaging. 2021; 37: 135-144
- Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction.J Am Coll Cardiol. 2013; 61: 2365-2373
- Global longitudinal strain by echocardiography predicts long-term risk of cardiovascular morbidity and mortality in a low-risk general population: the Copenhagen city heart study.Circ Cardiovasc Imaging. 2017; 10
- Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus.Cardiovasc Diabetol. 2016; 15: 22
- Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus.Cardiovasc Diabetol. 2015; 14: 37
- Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.J Am Coll Cardiol. 2014; 63: 2751-2768
- COVID-19 medical management including World Health Organization (WHO) suggested management strategies.Dis Mon. 2020; 66101068
- Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.J Am Soc Echocardiogr. 2005; 18: 1440-1463
- Left ventricular volume from paired biplane two-dimensional echocardiography.Circulation. 1979; 60: 547-555
- Normal ranges of left ventricular strain: a meta-analysis.J Am Soc Echocardiogr. 2013; 26: 185-191
- The Design and Analysis of Clinical Experiments.Wiley, New York–Chichester–Brislane–Toronto–Singapore1986 (432 S., £ 38.35. Wiley Online Library; 1988)
- The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the beck depression and anxiety inventories.Behav Res Ther. 1995; 33: 335-343
Sarıçam H. The psychometric properties of Turkish version of Depression Anxiety Stress Scale-21 (DASS-21) in health control and clinical samples. 2018.
- The Impact of Event Scale-Revised.in: Wilson JP Keane TM Assessing psychological trauma and PTSD: A handbook for practitioners. Guilford Press, New York, NY1997: 399-411
- Olayların Etkisi Ölçeği Türkçe versiyonunun geçerlilik ve güvenilirliği [Validity and Reliability of Turkish Version of “Impact of Event Scale-Revised”].New Symposium Journal. 2006; 44: 14-22
- Psychological status among different populations during COVID-19 epidemic: a systematic review and meta-analysis.J Tongji Univ. 2020; 41: 147-154
- Post-traumatic stress disorder, depression and anxiety symptoms in COVID-19 outpatients with different levels of respiratory and ventilatory support in the acute phase undergoing three months follow up.Minerva Med. 2022;
Kong X, Zheng K, Tang M, Kong F, Zhou J, Diao L, et al. Prevalence and factors associated with depression and anxiety of hospitalized patients with COVID-19. MedRxiv. 2020.
- Cardiovascular abnormalities and mental health difficulties result in a reduced quality of life in the post-acute COVID-19 syndrome.Brain Sci. 2021; 11
- 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.Lancet. 2021; 397: 220-232
- Psychiatric morbidity in survivors of the acute respiratory distress syndrome: a systematic review.Psychosom Med. 2008; 70: 512-519
- Impact of COVID-19 pandemic on mental health.Psychiatr Pol. 2020; 54: 187-198
- Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review.J Clin Psychiatry. 2011; 72: 233-239
- Stress and psychological distress among SARS survivors 1 year after the outbreak.Can J Psychiatry. 2007; 52: 233-240
- Posttraumatic stress after SARS.Emerg Infect Dis. 2005; 11: 1297-1300
- Long-term psychiatric morbidities among SARS survivors.Gen Hosp Psychiatry. 2009; 31: 318-326
- Post-traumatic stress disorder among COVID-19 survivors at 3-month follow-up after hospital discharge.J Gen Intern Med. 2021; 36: 1702-1707
- Influence of COVID-19 on general stress and posttraumatic stress symptoms among hospitalized high-risk patients.Psychol Med. 2020; : 1-2
- Psychological protective factors mediate the relationship between decision-making styles and mental health.Curr Psychol. 2020; 39: 1277-1286
- Association of coronary ischemia estimated by fractional flow reserve and psychological characteristics of patients.Postepy Kardiol Interwencyjnej. 2017; 13: 117-121
- Coronary artery disease in association with depression or anxiety among patients undergoing angiography to investigate chest pain.Tex Heart Inst J. 2009; 36: 17-23
- Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models.Stress. 2009; 12: 1-21
- Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study.Atherosclerosis. 2006; 185: 320-326
- Association between symptoms of depression and anxiety with heart rate variability in patients with implantable cardioverter defibrillators.Psychosom Med. 2009; 71: 821-827
- Catecholamines and estrogen are involved in the pathogenesis of emotional stress-induced acute heart attack.Ann N Y Acad Sci. 2008; 1148: 479-485
- Cardiac function associated with previous, current and repeated depression and anxiety symptoms in a healthy population: the HUNT study.Open Heart. 2016; 3e000363
- The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients.Brain Behav Immun. 2009; 23: 1140-1147
- Depressed mood and flow-mediated dilation: a systematic review and meta-analysis.Psychosom Med. 2011; 73: 360-369
- Left ventricular ejection fraction predicts severity of posttraumatic stress disorder in patients with implantable cardioverter-defibrillators.Clin Cardiol. 2016; 39: 263-268
- Socioeconomic inequalities in depression: a meta-analysis.Am J Epidemiol. 2003; 157: 98-112
- Obesity and subtypes of incident cardiovascular disease.J Am Heart Assoc. 2016; 5